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Resumo 
 
 
 
Atualmente, episódios de enfarte do miocárdio quando tratados com a devida urgência apresentam 
uma elevada taxa de sucesso. No entanto, a reperfusão de sangue no tecido resultante do alarga-
mento da coronária (técnica de tratamento mais usada), apesar de minimizar a perda de cardi-
omiócitos, tem impacto negativo a longo prazo. O desenvolvimento de novos fármacos para trata-
mento da isquemia tem sido dificultado pela escassez de modelos in vitro capazes de recriar o 
musculo adulto. No sentido de responder a estes problemas, encontram-se em desenvolvimento 
modelos in vitro recorrendo à tecnologia de organs-on-a-chip, que tem como objetivo recriar os 
fenómenos e interações celulares que acontecem no organismo. No âmbito do coração, esta tec-
nologia tem utilizado cardiomiócitos derivados de células estaminais pluripotentes, minimizando 
a necessidade de recorrer a produtos celulares de dadores humanos. Contudo, atualmente a dife-
renciação de células estaminais em cardiomiócitos é deficiente uma vez que as células obtidas 
apresentam reduzida maturidade a nível metabólico e estrutural. Esta limitação prejudica a utili-
zação destas células como modelos fidedignos do coração assim como a sua validade para o teste 
de novos fármacos. O plano de trabalhos aqui apresentado tem como objetivo desenvolver novos 
métodos de diferenciação de cardiomiócitos apartir de células puripotentes que promovam uma 
melhor maturação das células diferenciadas. Para tal foi desenhada uma abordagem inovadora que 
pressupõe a combinação de diferentes estímulos em níveis fisiológicos como forças mecânicas, 
nível de oxigénio e ainda substratos para a produção de energia. Paralelamente está a ser desen-
volvido e otimizado um chip para a simulação in vitro de isquemia e reperfusão, onde mais tarde, 
poderemos testar os cardiomiócitos adultos num cenário de doença. 
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Abstract 
 
 
 
Nowadays episodes of myocardial infarction when treated with due urgency, show a high success 
rate. However, reperfusion of blood on tissues, as a result from coronary elongation techniques 
(most common treatment technique), despite minimizing cardiomyocyte loss, has a long-term neg-
ative impact. The development of new drugs for the treatment of ischemia has been hampered by 
shortage of in vitro models capable of re-creating the adult muscle. To respond to these problems, 
novel in vitro organ-on-a-chip technologies have been developed, aiming at recreating cellular 
interactions observed in the organism. Concerning the heart, this technology has been using car-
diomyocytes derived from pluripotent stem cells, minimizing the need to resort to cellular prod-
ucts from human donors. However, current differentiation of stem cells in cardiomyocytes is yet 
deficient, as obtained cells show reduced metabolic and structural maturity. This limitation im-
pairs the use of this cells as bona-fide heart models as its validity for testing new drugs. The main 
goal of the work plan herein presented is to develop a new differentiation method to obtain fully 
mature cardiomyocytes from pluripotent stem cells. For that, we designed an innovative approach 
that combines the use of different stimuli at physiological levels such as mechanical forces, oxygen 
levels and even substrates for energy production. In parallel, a chip is being developed and opti-
mized for an in vitro simulation of ischemia and reperfusion, which can be combined with the 
mature cardiomyocytes to mimic the disease scenario ex vivo. 
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1. Introduction 
 
 
 
1.1 - Cardiac ischemic disease 
 
1.1.1 - Heart physiology  
The first organ to become functional during mammalian development is the heart. Heart 
size is tightly controlled to secure functional blood flood[1], being regulated by organ-intrinsic 
mechanisms but also extrinsic chemical and mechanical factors. Heart growth is separated in 
two phases, during fetal grow is achieved by hyperplasia, by cardiomyocyte (CM) prolifera-
tion[2],  while after birth it grows mainly by hypertrophy[3]. CM proliferation during develop-
ment is controlled by several growth factors such as insulin-like growth factors (IGFs), bone 
morphogenetic proteins (BMPs), Wingless-related integration site (Wnts) and neuregulins[4]. 
After birth CM complete the maturation process which is paralleled by an arrest in the cell 
cycle. 
The heart is comprised of diverse muscle and nonmuscle cell lineages: atrial and ventricular 
CMs, endocardial cells, valvular components, fibroblasts, conduction system cells, smooth mus-
cle and endothelial cells[5]. During cardiogenesis these different cell types are derived from 
distinct embryonic progenitor populations. The working force of the heart is provided by the 
CMs, which are differentiated cells with highly developed cytoskeleton (sarcomere system) and 
great metabolic capacity. CMs occupy most of the heart volume, despite not being the most 
abundant cell type[6].  
 
1.1.2 - Ischemia-Reperfusion  
Ischaemic heart disease is a major burden in Western world. Cardiovascular diseases asso-
ciated with ischaemia include myocardial infarction, stroke, pulmonary arteriole hyperten-
sion[7]  and coronary heart diseases. The cardiac injury during acute myocardial infarction 
results from ischemia and subsequent reperfusion. Myocardial ischemia occurs on a distal region 
to the occlusion of an epicardial coronary artery. The interruption of coronary blood flow leads 
to an inability of the myocytes to maintain steady state cellular metabolism attributable to 
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lack of oxygen and nutrients [8]. Thus, infarct size is a defining factor of long-term mortality 
and chronic heart failure, thus therapeutic intervention to limit the extent of necrosis during 
infarct episode has great individual and socioeconomic value. The level of ischaemic injury and 
the transition from reversible to irreversible damage is time dependent. As reperfusion is not 
quickly re-esteblished on the hypoperfused myocardium, this tissue becomes necrotic.  Even 
though reperfusion is crucial to partially retrieve the myocardial tissue affected, reperfusion 
can also accelerate the loss of CMs that have been severely compromised. CM calcium (Ca2+) 
loading is recognized as a major factor in acute ischaemia–reperfusion pathology, promoting 
cell death, contractile dysfunction and arrhythmic activity.  As the heart has very limited re-
generative capacity, the lost myocardium is replaced by fibrous scar tissue. Since scar tissue 
does not contribute to myocardial contractility, if the scar is large, global left ventricular (LV) 
contractile function is impaired, resulting in progressive chronic heart failure. Besides that, the 
scar also offers a barrier to the natural propagation of electric impulse. This repair process 
contributes to a progressive reduction on left ventricular ejection fraction (LVEF), which ex-
plains why myocardial infarction is one of the main causes of chronic heart failure worldwide. 
Deficit of oxygen during ischemia swings cardiac metabolism to anaerobic glycolysis, dis-
rupting ATP generation by mitochondrial oxidative phosphorylation (normally 95% of ATP pro-
duction in the heart), and thus reduces overall ATP availability[9]. This shift lead to accumula-
tion of glycolytic products, including lactate and protons, lowering intracellular pH and subse-
quent stimulation of Na+ ⁄H+ exchange to export protons that drive to extracellular acidosis. 
The Na+ ⁄H+ exchange continues until the cross-sarcolemmal proton gradient is dissolute. In 
parallel with pH variations, this mechanism also increases intracellular Na+[10] . In addition to 
Na+ ⁄H+ exchange other mechanism also contribute to a declined Na+ efflux, such as Na+ ⁄K+ ⁄ 
Cl cotransport[11] and the opening of voltage-gated Na+ channels,[12]as well as the deteriora-
tion in the activity of the Na+⁄K+-ATPase[13]. A reduced Na+ gradient during ischaemia impairs 
activation of a myriad of important signalling pathways, [14]resulting commonly on CM death. 
Infarct size may be easily limited by reperfusion, improving long-term myocardial function, 
reforming the healing pattern of the infarcted zone and reducing mortality. However, reperfu-
sion triggers additional harm to the myocardium, known as reperfusion injury. Altogether, the 
damage inflicted on the myocardium is better defined as ischemia/reperfusion (I/R) injury. 
Risk-adjusted treatments in-hospital reduced mortality from 20% in the late 1980s to 5% in 2008 
using reperfusion strategies and adjuvant pharmacology[14]. However, this drop-in mortality 
rates, have also resulted in augmented incidence of chronic heart failure. 
Rebuilding of coronary flow flushes away extracellular the acidosis, and establishes a regular 
transsarcolemmal pH gradient. This exacerbates Na+ ⁄H+ exchanger-mediated Na+ accumula-
tion as proton export is recommenced, resulting in Ca2+ overload via reverse-mode Na+ ⁄ Ca2+ 
exchange[15]. Numerous CM pathologies are associated with an excess in intracellular Ca2+[14]. 
For example, Ca2+ negligence in reperfusion is usually allied with systolic⁄diastolic dysfunction 
and arrhythmogenesis. Ca2+ can also overload and hasten CM death by multiple means. Hy-
percontracture and instigation of calpains, in mixture with cell swelling, cause sarcolemmal 
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rupture and non-programmed necrotic CM death. Amplified cytosolic oxidant environment and 
Ca2+  levels also promote mitochondrial Ca2+ loading, associated with opening of the mitochon-
drial permeability transition pore (mPTP) and programmed cell death by apoptosis.[16]  
Morphological typical features of reperfused myocardial infarction are karyolysis (chromatin 
total dissolution), contraction bands, membrane disruption, mitochondrial swelling, disruption 
in CMs, accompanied by microvascular destruction, interstitial haemorrhage and inflamma-
tion.[17] The heart was thought to be devoid of CM turnover after birth, however during the 
first decade of the 21st century, different populations of cardiac stem cells (CSC), poised for 
activation in response to injury, have been identified in the adult myocardium. These cells here 
thought to be able to regenerate the myocardium after myocardial infarction and were often 
tested in murine models of myocardial infarction.  CSCs are gathered together and coupled with 
the adjacent cells through the expression of gap and adherents junctions. Preservation of the 
undifferentiated state of CSCs appear to be sustained by adherents junctions. CSCs can also 
differentiate towards the endothelial and smooth muscle lineage. Altogether, despite heart 
damage cannot always be repaired intrinsically, this new insight opens new opportunities to 
different approaches in the prevention and treatment of ischemic pathologies.   
 
 
1.2 - Cardiomyocyte can be differentiated in vitro 
 
1.2.1 - Cardiomyocyte structure 
 CMs, are tubular shaped with diameters around 10 µm and 25µm with respective length 
between 30 and 100µm[18]. Due to the high metabolic behaviour in order to produce adenosine 
triphosphate (ATP), CMs have high number of mitochondria’s. These cells carry central nuclei 
and the cell also contain myofibrils organized in aligned sarcomeres through the cytoplasm[19] 
10. CMs form dense cellular networks, strongly attached top-to-top through intercalate discs 
(mechanic connection) also communicating through hiat junctions (electric connection).[18]  
Sarcomeres are multi-protein complexes forming basic units responsible for CM contraction. 
Sarcomeres are composed by two filament systems: thick filaments of myosin and thin filaments 
of actin, troponin and tropomyosin[18]. Sarcomeres are responsible for the CM striatum and 
could be divided in 4 microscopic distinct areas: 1) Z discs form the limit of each sarcomere; 2) 
I-bands containing actin and myosin filaments around Z disc; 3) an A-band is localized between 
two I-bands; and an 4) M line in the centre of sarcomere[19] 
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Figure 1.2.1.- “Schematic representation of the sarcomere. Sarcomeres are multi-protein complexes and 
the basic units of myofibrils.”[19] 
 
The size of each sarcomere is a determining factor for CM contraction strength . In physio-
logical conditions varies between 1.6 and 2.4µm, being the overlap above of actin and myosin 
filaments optimal for lengths of 2 to 2.4µm[18]. The contraction/excitation of CM is promoted 
by the universal herald of intracellular signalling, calcium ions (Ca2+)[20]. Ca2+ is essential to 
cardiac electrical activity, activating directly myofilaments contraction[21]. Cardiac contrac-
tility and relaxation modulation by intracellular calcium levels is an indispensable mechanism 
to the increase of myocardial strength induced by stress hormones (adrenaline) which increase 
the uptake of calcium during action potential[20].  Excitation-contraction coupling describes 
the processes required for electric excitation of the myocyte until the contraction of the 
heart[21]. The sarcolemma is the muscle cellular membrane, and in CM is characterized by 
invaginations named T tubules. T Tubules, are opened to the extracellular space allowing ionic 
exchanges necessary to electric depolarization and repolarization of cells. In the cytoplasm 
associated with T tubules, exists an extended network of tubular ramification called sarcoplas-
mic reticulum (RS), being composed by terminal cisterns on the limit next to T tubules. Between 
cisterns and tubules exists regions of electronic density, responsible for the detection sarco-
lemma depolarization and enabling Ca2+ entry through channels type L. The combination be-
tween Ca2+ influx and liberation increases the concentration of free Ca2+ that binds to troponin 
C originating a transformation in the shape of troponin that leads tropomyosin to shift its posi-
tion along the actin filament, thus allowing myofilament contraction between actin and myosin.   
 
1.2.2 - From stem cells to cardiomyocytes 
Human CMs used in in vitro experiments can be obtained from biopsies, or more recently, 
from stem cell differentiation into cardiac cells.  When stem cells (SC) were discovered during 
the 60’s of the past century, they were recognized as cells with self-renewal capacity, long 
term viability and multilineage potential. 
Since then different SC or SC-like populations were identified on almost every tissue in the 
human body. Well-defined SC pool are associated with tissues where differentiated cells have 
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a short lifetime, for example the blood, epidermis and intestinal epithelium which are tissues 
with high cellular turnover and regenerative potential, contrasting with the heart, retina and 
spinal cord.[22]  
 
 
Figure 1.2.2. - Resident stem cells determine the turnover of the  tissue.[22] 
 
In contrast to tissue resident stem cells, embryonic stem cells (ESC) can only be obtained 
through direct extraction from early developmental stages from pre-implantation mouse and 
human embryos and maintained in culture as undifferentiated cells. Using nuclear reprograming 
on somatic cells, resulting from nuclear transference of somatic cells (SCNT) or with pluripotent 
stem cells (iPSC) technology is also possible to obtain stem cells. ESC are able to proliferate 
indefinitily in vitro. They are derived from the inner cell mass (ISM) of the developing embryo 
(blastocyst), 5 days after fertilization, and have the potential to develop derivatives of the 
three germ layers, even after a long period of culture. In 1981, Evans & Kaufman derived the 
first ESC line from the inner cell mass of blastocysts which were maintained in vitro resorting 
to embryonic feeder cells (MEFs) and medium containing fetal calf serum (FCS). In 1998, Thom-
son and colleagues shown that ESC could also be isolated from human blastocysts. 
hESC present normal karyotype, express high levels of telomerase, express unique surface 
markers (e.g. SSEA-1/-3/-4 e TRA-1-60, TRA-1-81) that are not commonly expressed in other 
premature lineages or differentiated. ESC express high levels of telomerase activity. Telomer-
ase is a ribonucleic protein that adds telomeric repeats on chromosome extremities and is in-
volved in the maintenance of telomere length. Human differentiated cells do not express te-
lomerase, their telomeres shrink through life and enter replicative senescence after a finite 
number of divisions. Germ lines and embrionic tissues have high levels of telomerase. The te-
lomeric activity is the indicator of cell potential to proliferate, being the high level of telomer-
ase expressed in hESC suggesting that their lifespan will exceed the one verified on somatic 
cells. Although, hESC can be identified by high nuclear/cytoplasmic ratio, alkaline phosphatase 
and specific cell surface markers. In vivo teratoma formation is considered the golden standard 
for pluripotency evaluation. 
Blastocysts are not the only source of pluripotent ES cells. Pluripotent epiblast stem cells, 
known as epiSC, can be resultant from the postimplantation epiblast of mouse embryos [23]. 
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Gene expression profiling showed that hESC are more like epiSC than to mouse ESC[24]. Plu-
ripotent stem cells can also be derived from primordial germ cells, progenitors of adult gam-
etes, which diverge from the somatic lineage at late embryonic to early fetal development [25] 
Pluripotent cells can also be derived from reprogramming of adult somatic cells by transfer 
of the adult nucleus into the cytoplasm of an oocyte [26],[27]  or by fusion with a pluripotent 
cell[28]. Decades later, the work of Yamanaka showed that skin fibroblasts can be repro-
grammed to a pluripotent state using specific cocktail of factors, these cells were named in-
duced pluripotent stem cells (iPSC). A mechanism reproducible of reversion into a pluripotency 
state. Some premises were used to sustain this discovery: pack of transcription factors seem to 
be always present in pluripotency state in ES cells in vitro; a set of active genes are active 
relative to one another, hipomethyled. Using reporter gene to identify the modify cells where 
introduced with retrovirus transduction 24 factors. Some of genes were able to revert the cells 
into a pluripotent state, guiding to more tests that narrowed the gene list to four essential 
factors: Oct4, Sox2, Klf4 e c-Myc. Later studies using the same technique reported other tran-
scription factors Oct3/4, SOX2, Nanog, Lin28[28]. Reprogramed cells were like ESC, in terms of 
self-renewal capacity, differentiation potential, being able to give rise to cells of the three 
germ layers, and supported the information of teratomas in vivo. 
 
 
Figure 1.2.3. “Origin of stem cells. Cells are described as pluripotent if they can form all the cell types 
of the adult organism”[29] 
 
The efficiency of in vitro differentiation of pluripotent stem cells into CMs is poor and 
differentiated cells are normally a heterogeneous mixture of various cell types[30]. The prob-
lematic of using pluripotent stem cells is the necessity to acquire pure populations of differen-
tiated or committed cells, to circumvent the formation of teratomas[30]. The initial step during 
in vitro differentiation of CM from pluripotent cells, is stimulation of mesodermal lineages 
through activation of Wnt and nodal (TGF-β) [31]. Cardiogenic mesoderm is then induced by 
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Mesp1, promoting development of mesoderm precursors of the cardiovascular lineage as well 
as repressing the expression of key genes regulating other early mesoderm derivatives[32]. The 
final stage of differentiation to CMs is the differentiation of committed cardiac progenitors to 
beating CMs, stimulated and controlled by factors such as Wnt11[33]. The identification of ma-
turing CMs is commonly attained by confirming the presence of cardiac structural proteins such 
as α-actin, α-myosin heavy chain (α-MHC), BNP, islet-1140 or the cardiac isoform of Troponin-
T (cTnT).[34]  
 
 
1.3 - Cardiomyocyte maturation 
 
CMs maturity is commonly evaluated based on various characteristics: 1) cell morphology 
and sarcomeric length, alignment, organization and abundance; 2) metabolism; and 3) calcium 
mechanism. Through the comparison between CMs at different ontogenic stages and CMs gen-
erated in vitro, it was possible to establish that current hPSC derived CMs are equivalent to 
late fetal CMs. Structurally speaking, human adult ventricular CMs displays a surface area of 
10,000-14,000 µm2 [35] and length-to-width ratio r of 7:1 to 9.5:1[36]. Even after cellular dis-
sociation, the adult CM structure is commonly maintained due to the highly organized internal 
architecture. CM size and shape is functionally important, as an indicator of internal organiza-
tion which is relevant for a variety of functional properties such as impulse propagation, action 
potential depolarization velocity, total contractile force and membrane capacity (directly re-
lated to cell surface area). The average length of a relaxed sarcomere is 2.0-2.2µm. The well-
developed and abundant sarcomeres in adult CMs portrait myofibril perfect alignment being 
evident in electron microscopy images where the sharp, highly aligned organized Z-disc struc-
tures can be observed. The contractile stress, myocardial fibres force per unit area, is devel-
opmentally-regulated, having adult CMs more force than fetal counterparts. The active stress 
created by freshly harvested human ventricular CMs is >50 mN/mm2 [37]. Action potential prop-
agation is anisotropic as a result of the high concentration of gap junctions in the intercalated 
discs and low concentration at the lateral cell CM borders[38]. Adult CMs excitation-contraction 
coupling is intermediated mainly by calcium-induced calcium release, showing a positive force-
frequency association when paced[39],[40].  Myosin heavy chain structural protein isoform and 
beta-myosin heavy chain (b-MHC), are predominant in adult ventricular CMs while the opposite 
is verified for alpha-myosin heavy chain (a-MHC)[41]. Other structural protein is MYBPC3 en-
codes for the thick filament associated protein cardiac myosin-binding protein C, a signalling 
node in cardiac myocytes that contributes to the maintenance of sarcomeric structure and reg-
ulation of contraction and relaxation[42]. 
During development, oxygen and nutrients requirements increase, as well the distance that 
they need to be transported. Hence, as development progresses blood flow rises, intensifying 
the hemodynamic loading on CMs resulting therefore in increased fibre length, contractile force 
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and stroke volume according to Frank-Starling mechanism. The latter is deceptive in human 
fetal heart from 10 to 15 week of gestation[43]. Increased Ca2+ sensitivity has been accredited 
to this mechanism, impacting specially at longer sarcomere lengths that induces an increase in 
the force of contraction [44]. 
 Fetal CMs have an average length of a sarcomere in a relaxed state of 1.8μm and have a 
surface area ranging from 1,000–1,300μm2 [45]. Fetal CM isolated from human foetus between 
14 to 19 week, show a contractile stress of 0.4mN/mm2 [46] whereas neonatal CMs generate a 
contractile stress of 0.8–1.7 mN/mm2 [47]. Measuring with same experimental setting, neonatal 
CMs dramatically rise their contraction capacity as the contractility machinery matures, causing 
a two or threefold increase in strength compared to the fetal period. The immature asynchro-
nous beating behaviour of early fetal CMs is related to the randomly distributed proteins along 
the cell membrane as CMs at this stage still lack of distinguishable intercalated discs. Fetal CMs 
are also immature electrophysiological level. The depolarization velocity of fetal CMs ranges 
from a 6 to 50-fold lower, compared to adult CMs. Some maturation transformations are par-
ticularly evident during around birth as CMs switching from hyperplastic growth to hypertrophic 
growth [35],[48].  
The similarity of hPSC-derived CMs to fetal CM stages of maturation, has been well do-
comentend at several levels. Sarcomeres in hPSC-CMs display reduced contractile protein or-
ganization with very low myofibrillar density as shown by sarcomeric α-actinin staining[49], size 
wise they are also 25 to 30% shorter than in adult CMs and 6–11% smaller than in fetal CMs (1.6–
1.7μm [50]. However, long-term culture (80–120 days) may increase the sarcomeres length of 
the hPSC-CMs to the same size of fetal CMs. hPSC-CMs have less defined sarcomeric structures 
and reduced organization comparatively to fetal CMs[51][46]. Sarcomeres underdevelopment 
relates to the lack of organization that support different myofilament regions[52], creating 
unaligned Z-discs of variable width[53], reduced quantity and an uneven distribution through-
out the cell, also being sarcomeres more concentrated in the perinuclear region[54]. Proteins 
responsible for sarcomeres contraction can be detected in PSC-CMs, nevertheless at a much 
lower level of expression comparing to adult CMs. During fetal stages MHC is the predominant 
isoform. Long-term culture, also improves hESC-CMs machinery organization despite not con-
tributing to t-tubule[49] or M band formation[50], demonstrating that functional maturity was 
not reached. Immature asynchronous beating observed in hESC-derived CMs is related to the 
randomly distributed proteins along the cell membrane with lack distinguishable intercalated 
discs, and has been reported to range from 21 to 84 beats per minute. Measured with same 
experimental setting, the contractile stress of seeded fetal cells aged between 14 to 19-week 
CMs was 0.4mN/mm2 [46]  and 0.15–0.30mN/mm2 for hPSC-CMs[55]. The calcium kinetics of 
hESC-CMs is similar to fetal CMs with low amounts of CASQ2, RyR, SERCA, and L-type calcium 
channels, possessing little SR function and t-tubules, relying mostly on trans-sarcolemmal cal-
cium intake to rise intracellular calcium[49]. SERCA2 gene encodes Ca(2+)-ATPases, which are 
intracellular pumps located in the sarcoplasmic or endoplasmic reticula of muscle cells, cata-
lysing the hydrolysis of ATP coupled with the translocation of calcium from the cytosol into the 
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sarcoplasmic reticulum lumen while phospholamban (PLN) encodes a key regulatory protein of 
cardiac diastolic function, modulating calcium re-uptake during muscle relaxation, so that plays 
an important role in calcium homeostasis in the heart muscle. Previously mentioned genes have 
enhanced expression on mature CMs[56]. 
CMs in the myocardium are subjected to three types of persistent mechanical stimuli that 
influence their development: stretch during heart filling, hemodynamic compression from blood 
circulation and active self-induced cytoskeletal contractions[57]. Cellular mechanotransduction 
is the mechanism by which cells convert mechanical stimuli into biochemical reactions.[58] In 
vitro cells tend to sense and respond to external forces, changing the assembly of molecules 
promoting an alteration in their function. The structures mostly affected are the cytoskeleton, 
surface processes, adhesion proteins, nuclear lamina and stretch-activated channels.[58] Cell 
cytoskeleton is the basic support to cellular organelles, providing the physical edifice of cells. 
It comprises a network of actin and tubulin filaments and tubules that are disseminated over 
the entire cytoplasm. Any force transfers from inside (contraction) or outside (mechanical pres-
sure) the cell leans towards it. The cytoskeleton has been shown to be a tensegrity (tensional 
integrity) structure with elements under compression (microtubules) that are held together by 
elements under tension (microfilaments, intermediate filaments).[59] To detect extracellular 
“aggressions” cells developed protrusions, as primary cilia, including itself receptors and chan-
nels that can be triggered through the physical activation of these processes by external 
forces[60]. This “aggressions” are promoted by the attachment to the extra cellular matrix 
(ECM) and to other cells. To promote this connections in cell-ECM contact exist specialized 
membrane proteins (integrins)[61], as well for cell-cell contact (cadherins and gap junc-
tions)[62],[63]. Biochemical changes resultant from mechanical stimuli can have immediate im-
pact, at the cell membrane via conformational variations in membrane proteins, also transmit-
ted to the cytoskeleton inside the cell. This interactions on CMs were proved to influence func-
tional characteristics as impulse propagation[64],[65], contractile force output  and excitation–
contraction coupling[66]. In vivo mechanotransduction signalling permits the cytoskeleton to 
remodel in reply to changes in the load on the myocardium, altering CMs aspect ratio and 
sarcomere density in an attempt to maintain cardiac output, proving the role of cytoskeletal 
architecture on responses to extracellular mechanical stimuli[36], [64], [67], [68]. The long-
term impact involves changes in gene expression, happening due to downstream reactions from 
mechanical stimuli[69]. It is also thought that some direct force is applied in the nucleus as a 
result of the direct connection between nucleus chromatin and lamina with the cytoskeleton, 
this way transferring forces to the nucleus[70]. During heart development, CMs experience 
morphological changes as they advance toward the adult phenotype[53], organizing into lami-
nar sheets of muscle tissue[71]. Cytoskeleton actin remodelling in confined regions of CMs, 
being identified as modifier of cell shape that drive looping of the heart tube during embryonic 
development [36]. Following a Natural Engineering philosophy, in vivo mechanical environment 
of cells can be replicated in vitro, including substrate stretching to which cells are attached, 
shear stress caused by fluid flow over cells, compressive forces (hydrostatic pressure), substrate 
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stiffness altering and shifting substrate topography. Additional techniques such as traction force 
microscopy, micropillar arrays, magnetic tweezers, optical tweezers, and atomic force micros-
copy have been employed along with force quantification to comprehend mechanotransduction 
mechanisms[72]–[74]. CMs are uninterruptedly subjected to cyclic mechanical strain made by 
rhythmic heart beating. Adult CMs begin to dedifferentiate when they are placed in 2D culture 
without mechanical loading. Zimmerman, Eschenhagen and colleagues proved that seeding im-
mature CMs in suitable 3D matrix and exposing them to mechanical stress will enhance their 
maturation[75].  
The correlation between physiological levels and the standard values used nowadays to 
culture cells need an approximation, specifically the case of atmospheric gases and stem cells 
and respective differentiation into specific cell lines, for example  what is consider hypoxic 
environment, are the pO2 values, 3–5%, required to maintain the full pluripotency of mammalian 
ES cells[76]. It was demonstrated that human ES cells proliferate have a similar development 
when cultured at 3–5% O2 as they do under 21% pO2, yet, analysis of morphology and the loss 
of stem cell markers such as stage-specific embryonic antigen (SSEA) and the transcription fac-
tor OCT4, was substantially reduced. Physiologically normoxic conditions for embryonic or adult 
cells fluctuates broadly, between 2% (14.4 mm Hg pO2) and 9% (64.8 mm O2 Hg). Previously to 
the formation of circulatory system, human development occurs in a relatively O2-poor envi-
ronment (3%-4% O2)[77]. To assure acceptable O2 demand, foetuses present diverse strategic 
variations as higher heart rate, higher haemoglobin concentration and a large surface area for 
gas exchange in the placenta[78]. Organisms have mechanisms at molecular level to preserve 
O2 homeostasis, hypoxia-inducible transcription factors (HIFs), the environmental sensing mam-
malian target of rapamycin (mTOR) and the endoplasmic reticulum (ER) stress response[79]. 
Placentation is the initial step of development of the embryo on mammalian development and 
it occurs in a low oxygen ambient. At this stage there is no blood flow from the mother into the 
emerging placenta until the 3rd month of gestation, essential due to tissues immaturity to 
protect themselves against oxidants[80]. Entering the second trimester maternal flow is set, 
after the collapse of endovascular trophoblast plugs rising the placental pO2 to values above 
50 mmHg.[81] The placental pO2 keeps this values until birth. pO2 should be ponder as a devel-
opmental morphogen that influences cell fate in a similar way to the more traditionally recog-
nized gradients of secreted growth factors. Adult CMs produce their energy mostly from oxida-
tive metabolism, with 90% of their acetyl-CoA created from oxidation of fatty acid[82]. Fat 
provides 60% of energy while anaerobic metabolism accounts for less than 1%. Also, in adult 
CMs glycogen lodges 2% of cell volume[83] and mitochondria’s 20%-40%[84]. Cardiac tissue suf-
fers a developmental conversion from using glycolysis into fatty acid based oxidative phosphor-
ylation (OXPHOS)[85]. In order to support directly the energy necessities (ATP) for cell contrac-
tion, mitochondria with well distributed lamellar cristae are crowded below the sarcolemma or 
along myofibrillar proteins such as sarcomeric α-actinin to form functional energetic units[37]. 
Embryonic and fetal CMs create their ATP mainly through glycolysis, being oxidative metabolism 
eligible for less than 15% of the total acetyl-CoA production[53]. Also, in fetal CMs glycogen 
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ocuppies 30% of the cell volume[86] and mitochondria account for a small fraction of cell vol-
ume. Mitochondria are dispersed across cytoplasm and have the morphology of a vesicle be-
cause of the absence of complete cristae in the inner mitochondrial membrane[87]. Birth brings 
metabolic pressure because there is an increase in contractile function, cells experience fatty 
acid as a substrate for energy, and oxygen levels rise rapidly. This phenomenon triggers neona-
tal CMs to change to oxidative metabolism with an increase in mitochondria size and amount, 
development of cristae, and a more ovular-shaped mitochondria morphology[88]. Fetal mito-
chondria are randomly distributed, mostly in the perinuclear region (by this time they are 
mostly needed in this area, due to highly hyperplastic behaviour of fetal CMs requiring lots of 
cell energy to sustain the nuclear activity) also containing less dense myofibrillar structures. 
Metabolically hPSC-CMs are identically to fetal CMs being predominantly glycolytic and express-
ing oxidative phosphorylation genes although at low levels. Immature CMs seem to rely on gly-
colysis and lactate oxidation (majority of myocardial oxygen consumption[89], as a source of 
energy, with mitochondrial oxidative metabolism from fatty acids a minor contributor.[90] Lac-
tate production from glycolysis (accumulated from pyruvate degradation) exists even in the 
presence of adequate levels of oxygen. Mature and differentiated CM possess increased mito-
chondrial oxidative capacity, with fatty acid B-oxidation the main energy supplier. Fatty acid 
(FA) handling is a fundamental metabolic feature for mature CMs the  transition is supported 
by genes like carnitine palmitoyltransferase1B (CPT1responsible for the import into the mi-
tochondria of long-chain fatty acyl-CoAs,  peroxisome proliferator-activated receptor alpha 
(PPARFA concentration transducerworking as a member of the nuclear receptor family of 
ligand-activated transcription factors that regulate gene expression and hydroxyacyl-CoA de-
hydrogenase trifunctional multienzyme complex subunit beta (HADHB) responsible for mito-
chondrial trifunctional protein, which catalyses the last three steps of mitochondrial beta-oxi-
dation of long chain fatty acids. However, developed CMs diet is ‘‘omnivore’’, meaning that if 
necessary, they are able to oxidize glucose, lactate, ketones, and amino acids to produce en-
ergy[91],[92].Catabolic pathways of different energetic substrates, converge on acetyl-CoA pro-
duction which is further used for ATP production[93]. The cardiac metabolism is known to be 
extremely flexible in using different substrates depending of their availability. This kinetics is 
maintained by hexokinases responsible for the first step in most glucose metabolism pathways, 
phosphorylating glucose to produce glucose-6-phosphate. Hexokinase 1 (HK1) is the isoform 
ubiquitously expressed in most tissues, whereas hexokinase 2 (HK2) is the main form found in 
skeletal muscle. Kinetics is also impacted by pyruvate dehydrogenase kinase 1 (PDK1) playing 
a key role in regulation of glucose and fatty acid metabolism via phosphorylation of the pyruvate 
dehydrogenases regulates metabolite flux through the tricarboxylic acid cycle, down-regulating 
aerobic respiration what inhibits the formation of acetyl-coenzyme A form pyruvate. Glucose 
transporters (GLUTs) on CMs have isoforms one and four as the most abundant. GLUT1 is mainly 
localized on plasma membrane, being responsible for a significant component of basal cardiac 
glucose uptake, while GLUT4 is mostly present in the intracellular vesicles at resting stages, 
and is translocated to the plasma membrane upon insulin stimulation. GLUT1 is predominant in 
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the embryonic and neonatal heart and GLUT4 is upregulated after birth while GLUT1 is down-
regulated, subsequently GLUT4 is primary glucose transporter on mature CMs. [94] 
Metabolic alteration occurs only after birth (birth shock), when oxygen levels are abun-
dant[85]. Subsequently to birth, foetus blood levels of lactate decrease from 5–7 mM to approx-
imately 0.5 mM in the adult circulation[95], while the levels of free fatty acids are very low in 
the fetal circulation, less than 0.1 mM, increasing immediately after birth to levels between 
0.2–0.4 mM[95],[96] Notwithstanding this increase, fatty acid oxidation rates are kept low in 
the immediate neonate period, providing less than 15% of the cardiac ATP demands, thanks to 
an inhibition of mitochondrial fatty acid uptake[97]. The behaviour of CMs is responsive to the 
environment and energy capacities. Developing CMs proliferate in a relative low oxygen (3-5%) 
environment in the womb[98] and the metabolic phenotype provides the biosynthesis of cellular 
lipids, amino acids, nucleotides, and other macromolecules, all indispensable to produce 
enough material to form viable daughter cells.[99], Glycolytic metabolism seems to facilitate 
the maintenance of pluripotent and proliferative states.[90] The contractile capacity of mature 
CMs is generated through ATP production by OXPHOS. Increased mitochondrial oxidative capac-
ity on CMs seems to be a mark of the switch to a more terminally differentiated state[59]. 
Mitochondria are responsible for producing more than 95% of the ATP used by CMs. If ATP pro-
duction is aborted, the human heart is only capable of beating for few seconds since CM storage 
is minimal[100]. The contribution of glucose to energy production is very small, with the ma-
jority of energy being derived from fatty acid oxidation. Nevertheless, glucose is very important 
among myocardial substrates since it can give a small quantity of ATP through substrate-level 
phosphorylation during glycolysis, which occurs in the in the extra-mitochondrial compartment. 
This is crucial in ischemic conditions where oxygen levels are low[101] . Conversion from an-
aerobic glycolysis to mitochondrial oxidative phosphorylation guides the differentiation of ESC 
to CMs.[90] Such mechanisms are involved in regulation of both glycolysis and oxidative metab-
olism in undifferentiated stem cells verifiable also during cardiogenesis in the embryo in vivo, 
the transition from the immature metabolism into the mature metabolism is secured by a set 
of genes being PGC-1 an excellence marker for this phenomenon. Catabolic pathways of dif-
ferent energetic substrates, converge on acetyl-CoA production which is further used for ATP 
production[93]. The cardiac metabolism is known to be extremely flexible in using different 
substrates depending of their availability. Yet, metabolic immaturity of hESCs-differentiated 
CMs was verified by our group, revealing a fetal like metabolic behaviour. This phenomenon is 
also observed in in vitro cell cultures where high concentration of glucose is used. In this sce-
nario cells generate energy through aerobic glycolysis instead of mitochondrial oxidative phos-
phorylation (OXPHOS), even though sufficient oxygen is present. For the first time observed in 
cancer cells, this event was designated as the Warburg effect[102]. 
The metabolic immaturity of CMs as revealed in both low or high O2 setups cells always 
prefer to use glycolysis, being shown in some cases with only 0,1% of O2, the cells can survive 
when they were expected to die. To mimic in vitro, the cardiac in vivo environment, and get 
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valid cells to use in further studies, diverse groups are using glucose deprived medium supple-
mented with galactose to trigger the use of OXPHOS metabolism. Although this metabolic swift 
has been observed, the underlying mechanisms are yet to be revealed. Some reports suggest 
relates with galactose handling by the cell i.e. the rate at which galactose is metabolised is 
much slower than glucose. Initially ATP is used to convert glucose to glucose-6-phosphate, while 
galactose-1-phosphate is theoretically not converted directly and passively to glucose-6-phos-
phate, turning the conversion slower. It requires the uridyltransferase to swap the galactose-
1-phosphate with glucose-1-phosphate, which is then mutated to glucose-6-phosphate (Leloir 
pathway). This uridyltransferase requires UTP, which is synthesized from UMP using two ATP 
molecules (UMP->UDP->UTP). This is essentially where the extra ATP usage comes into play 
because with glucose transferase or UTP are not required. Production of pyruvate via glycolytic 
metabolism of glucose profits 2 net ATP, while the production of pyruvate via glycolytic me-
tabolism of galactose yields has no ATP profit[102]. Therefore, cells are forced to use glutamine 
(highly abundant in culture media) and shift towards aerobic metabolism, resulting in a rise in 
the oxygen consumption rate compared to cells grown in glucose media[103],[104]. This way, 
the fact that galactose is carried into the cell at a slower rate than glucose, its conversion also 
takes longer, makes it a kinetic phenomenon as well. Altogether, galactose limits the carbohy-
drate flux into a cell, which enables the cell to adapt and utilize OXPHOS more regularly[103], 
[105]–[107]  Reitzer et al. suggested that glutamine provides energy by aerobic oxidation from 
the citric acid cycle metabolism when carbohydrate are used in the culture medium is galac-
tose[107]. Gohil et al. showed that human MCH58 skin fibroblasts cultured in glucose derive 
ATP from both aerobic glycolysis and mitochondrial glutamine oxidation. On the other hand, 
when cells are cultured in galactose they have a five to six-fold decrease in the extracellular 
acidification rate (ECAR), which means that there is a decrease in glycolysis. Additionally, a 
twofold increase in the oxygen consumption rate (OCR), consistent with a shift to glutamine 
oxidation was also observed. Via a mixture of β-adrenergic stimulation (isoproterenol) and fatty 
acid supplementation to mimic post-natal developmental processes[108] our group was able to 
increase mitochondrial expression of enzymes of the electron transport chain complexes I to IV 
on cells supplemented with galactose and fatty acid. Nevertheless, the levels of expression are 
still lower than in adult CMs. 
 
 
 1.4 - Organ-on-a-chip technology  
 
Organs-on-a-chip is a recent technological development with the potential to address dif-
ferent problematics. Concerning preclinical drug testing, the present golden standard is to first 
test drug in vitro before proceeding to animal models (in vivo). Besides being extremely ex-
pensive, labour-intensive and ethically contentious[109], animal testing habitually lacks pre-
dictive value[110], which is demonstrated by the large percentage (88%) of drugs eventually 
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failing in clinical trials[111]. The lack of predictive value can be attributed to the differences 
in pathophysiology between humans and genetically modified animal[112]. Variations occur in 
species-to-species expression profiles of transporter proteins[113]  and in the electrophysiology 
of the heart muscle[114] . In order to surpass interspecies differences, human cells can be used 
in in vitro tests, however, these models are too simplified to authentically replicate the micro-
environment of a tissue. In addition, cells in culture, in the absence of the native environment, 
tend to lose their specific tissue physiology[115]. Organ-on-chip models have the capacity to 
resolve some of these limitations[115]. They contain micrometre-sized channels in which cells 
can be cultured, allowing the precise control of the culture environment, trying to simulate the 
microenvironment of a certain organ by tuning mechanical, biochemical and geometrical as-
pects, resulting in a more predictive outcome.[115] Organs-on-chips can be engineered in such 
a way that they allow direct measurements of organ function as well as pharmacokinetics and 
pharmacodynamics, assisted by high-throughput mechanisms[116]. The ultimate goal of this 
technology is to create a natural engineering device, mimicking functional units of a certain 
organ rather than a complete organ, in order to work out a realistic but simple in vitro mod-
els[116]. Organ-on-chip devices created a big suspiciousness in the beginning. However, several 
proof-of-principle studies such as lung-on-a-chip[117], bacteria-inhabited gut-on-a-chip[118] 
and the atherosclerosis-on-a-chip[119], proved the robustness of this technology, namely for 
evaluating organ functions and physiological responses to stimuli that were not be tested before 
in vitro. 
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2 - Material and methods 
 
2.2.1 - Stem cell maintenance  
Delta-N3 hESCs were cultured with Essential 8 Medium (Life Technologies) containing 50 
Ul/ml penicillin/streptomycin (P/S, ThermoFisher) on 6 well-plates (Greiner) coated with Vit-
ronectin (Life Technologies). The cells were incubated at 37°C in humidified air with 5% CO2 
and with 4%/21% O2. Stem cells were passaged for subculture or differentiations at a time of 
high confluence without individual colonies connecting to eachother.  
 
2.2.2 - Feeder-free monolayer differentiation of hESC to cardiomyocytes 
Differentiation protocol was proceeded on 6 well-plates(Greiner) pre-coated with Matrigel 
(Corning). On day minus one (D-1) wells were seeded with 250 000 hESCs per well in E8 medium 
and cultured overnight. On day zero (D0), medium was replaced by BPEL medium (3 ml/well), 
plus growth factors by adding (to a final concentration) 20 ng/ml ACT-A (Miltenyi), 20 ng/ml 
BMP4 (R&D Systems) and 1.5 µM CHIR(Axon Medchem). On day 3 (D+3) medium was refreshed 
with the prepared BPEL + 50 µg/mL Matrigel (Corning) + 5 µM XAV 939 (R&D Systems), final 
concentrations. On days D+7, D+10 and D+14 medium was refreshed with BPEL medium without 
any additions. Cell dissociations for subsequent experiments were usually done at D+13. 
 
2.2.3 - Preparation of BPEL medium 
Please refer to table 1 in the appendix 
 
2.2.4 - Matrigel well-plate preparation 
Matrigel stocks (Corning) were kept on ice during procedure to avoid gelatinization. Matrigel 
Matrix GFR was diluted to a concentration of 83 ug/mL using serum-free medium (DMEM-F12) 
using ice-cold pipette tips. One millilitre of diluted Matrigel suspension was added per 6-well; 
the plate is then incubated for 60 minutes at RT before use, or stored at 4oC with an additional 
mL of DMEM per well for later use. 
 
2.2.5 - Hypoxia equipment  
Biospherix Xvivo System was used in hypoxia experiments. The working chamber was set to 
37ºC, variable O2 percentage depending on the current work being executed and 5% CO2. The 
incubation chamber used to expose cells to hypoxia contained a humidified, variable O2 per-
centage depending on the current work being executed and 5% CO2 atmosphere at 37ºC. Nikon 
eclipse TS100 microscope was used to image within the hypoxia system. 
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2.2.6 - Chip fabrication 
The microfluidic chips were produced by polydimethylsiloxane (PDMS) by soft lithography. 
In short, silicon wafer moulds with SU-8 microstructures were designed and produced as de-
scribed previously (van der Helm, Odijk et al. 2016). PDMS base and curing agent were mixed 
in a 10:1 wt/wt ratio (Sylgard 184 Silicone elastomer kit, Dow Corning, Midland, MI, USA). After 
degassing the mixture, the PDMS was poured onto the SU-8 patterned silicon wafer and cured 
for at least 3 hours at 67°C. The cured PDMS with channel imprints was then cuted in individual 
chip blocks. After that, four inlets (1.2 mm in diameter) were punched into the block. Dust was 
removed using Scotch tape (3M). Microscope slides were spin-coated with 1:10 PDMS mixture 
and cured at 67oC for 60 minutes. PDMS block and spin-coated microscope slide were then 
covalently bonded by air plasma activation of the surfaces (50 W) for 40 s (Cute, Femto Science) 
and gentle assembly, followed by a post-assembly bake of 60 minutes at 67oC, then were coated 
with 83 µg/mL Matrigel (Corning) or Vitronectin 5 ug/mL (Life Technologies). Chip dimension 
was approximately 26 mm x 26 mm, composed by 7 channels separated with a PDMS barrier 
with pores of 3µm every 10 µm, as demonstrated on figure 2.2.6.1. Channels dimensions were 
8000 µm in length, 300 µm wide and 58 µm height. Inlets and outlets 1.2mm of diameter.   
 
 
Figure 2.6.1. Illustrative image of chip design 
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2.2.7 – CMs seeding on chip 
Chip channels were incubated with Matrigel solution as mentioned at point 2.2.4. Due to 
the small dimension it was only added 20µL per channel. 
CMs dissociation (2.2.x). CMs counted on Neubauer Chamber (Sigma Aldrich), following a pro-
cedure of concentration or dilution, in order to produce a solution with 8× 106 cells/mL to 
10×106 cells/mL after. In each channel through the inlets it was added 10µL of cell solution. 
 
 
2.2.8 - RNA isolation  
RNA isolation was performed with RNeasy Mini Kit (Qiagen) (74104). Kit protocol was fol-
lowed, isolation was done at room temperature. The concentration and purity of RNA were 
measured by NanoDrop® ND-2000 spectrophotometer (Thermo Fisher Scientific), assuming as 
ideal ratio values of A260/A 280 between 1.8 and 2.1. Isolated RNA is kept on ice during han-
dling and stored at -80oC for later use. 
 
2.2.9 - cDNA synthesis  
cDNA synthesis from RNA isolation was performed using the iScript™ cDNA Synthesis Kit (Bio 
Rad, 1708891). Kit protocol was followed. 
 
2.2.10 - qPCR 
qPCR was performed on cDNA obtained using the Sensimix kit (GC Biotech) (QT615-20ac-
cording to the manufacture instructions. Primers sequnces are detailed in Table 1. 
 
 
2.2.11 - Fluorescence imaging  
Double reporter cell line, with GFP driven by an NKX2.5 promotor and an Actinin-mRu-
byII fusion protein was created in our group (unpublished data) through CRISPR mediated gene 
Function Full name Symbol Primer Name sequence 5'-> 3'
PPARa fwd GCCTAAGGAAACCGTTCTGTG
PPARa rev TCCGACTCCGTCTTCTTGATG
GLUT-4 fwd GCCGGACGTTTGACCAGAT
GLUT-4 rev GGTGTTTCACCTCCTGCTCTA
GLUT-1 Fwd TCCACGAGCATCTTCGAGA
GLUT-1 Rev ATACTGGAAGCACATGCCC
HK1 fwd GGACTGGACCGTCTGAATGT
HK1 rev ACAGTTCCTTCACCGTCTGG
HK2 fwd CAAAGTGACAGTGGGTGTGG
HK2 rev GCCAGGTCCTTCACTGTCTC
LDHB fwd CTCCTGTGCAAAATGGCAAC
LDHB rev CCTAGAGCTCACTAGTCACAG
PDK1 Fwd CCGCTCTCCATGAAGCAGTT
PDK1 Rev TTGCCGCAGAAACATAAATGAG
HADHB Fwd ACACTGTCACCATGGCTTGT
HADHB Rev CTGGCCAGAAGCAATCAAG
CPT-1b Fwd CAGGCGAGAACACGATCTTC
CPT-1b Rev GCGGATGTGGTTTCCAAAG
PGC-1a Fwd TGGTGCCACCACCATCAAAGA
PGC-1a Ver TCACCAAACAGCCGCAGACTG
MYH6 Fwd GACTGTTGTGGCCCTGTACC
MYH6 Rev GGAAGGATGAGCCCTTTTTC
MYH7 Fwd GGAGTTCACACGCCTCAAAGAG
MYH7 Rev TCCTCAGCATCTGCCAGGTTGT
PLN Fwd CTCACTCGCTCAGCTATAAGAAG
PLN Rev AGAGAAGCATCACGATGATACAG
MYBPC3 Fwd GTCCCAAAGGGTCAAGCTCA
MYBPC3 Rev ATGCGCTCGTACTCAGATGG
SERCA2 Fwd ATGCACCTTGAGGACTCTGC
SERCA2 Rev ATCATGATGACCCGGATGCC
Metabolic
Peroxisome proliferator-activated receptor alpha PPARa
Glucose transporter type 4 GLUT-4
Glucose transporter type 1 GLUT-1
Hexokinase 1 HK1
Hexokinase 2
CPT-1b
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha PGC-1a (PPARGC1A)
HK2
Lactate dehydrogenase B LDHB
Pyruvate Dehydrogenase Kinase 1 PDK1
ATPase Sarcoplasmic/Endoplasmic Reticulum Ca2+ Transporting 2 ATP2A2
Contraction Mechanism
Myosin heavy chain 6 a-MHC
Myosin heavy chain 7 b-MHC
Phospholamban PLN
Myosin Binding Protein C, Cardiac MYBPC3
Hydroxyacyl-CoA Dehydrogenase Trifunctional Multienzyme Complex Subunit Beta HADHB
Carnitine palmitoyltransferase 1B (fatty acids)
18 
 
editing. A reporter for -actinin, a protein localized at Z-disc of microfilaments and analogous 
dense bodies, helping to anchor the myofibrillar actin filaments, enables imaging of sarcomeres. 
Imaged in a Nikon TE2000U (10x or 20x Nikon objective) or a EVOS FL (ThermoFisher) (respective 
objectives 10x and 20x). 
 
2.2.12 - Dissociation of hESC-derived cardiomyocytes 
CMs on the wells were washed with 2-3 ml PBS (Thermo Fisher). Next, it was added 1000 µl 
1x or 10x TrypLE (Thermo Fisher) (depending on day after differentiation, older cells were 
harder to detach). Incubated for 10 min. Finally, it was added 4 ml BPEL medium to the cells 
to inactivate the TrypLE. 
 
2.2.13 – Mitochondria staining   
Mitochondria phenotype and location is addressed using MitoTracker® Deep Red FM (Ther-
moFisher) (M22426), far red fluorescent dye (abs/em 644/665 nm) that stains mitochondria in 
live cells. Final solution of 40nM. Cells were loaded with Hoerst (Sigma Aldrich) and MitoTracker 
Far Red (CMs, 40 nM, Invitrogen) in the above experimental buffer for 20 minutes, thenimaged 
in experimental buffer with a Nikon TE2000U, custom-built on-stage incubator to keep the plate 
in the proper experimental conditions, the objective was a NIKON CFI super fluor 40x /1.30 oil 
immersion objective or quantified by flow cytometry (2.2.14). 
 
2.2.14 - Flow cytometry 
Sony SH800S Cell Sorter, was used to obtain and quantify the different population of cells 
in a dish after a differentiation for further analysis of the mechanism promoting this differen-
tiation. CMs were dissociated (2.2.x) from each well. Solution was centrifuged for 3min, 2400 
RPM, and supernatant removed. Cells were resuspended on FACS buffer, and placed on FACS 
tubes after passing the strainer.  
 
2.2.15 - Statistical analysis 
Statistical analysis was performed using GraphPad Software. Error bars represent mean  
S.E.M. unless stated otherwise.  
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3. – Results 
3.1. Embryonic pO2 levels support maintenance and recovery of cryo-
preserved hESC. 
Atmospheric levels of oxygen (21% pO2) and conventional tissue levels of carbon dioxide 
(CO2) (5% CO2) are generally used as standard conditions for in vitro cell culture. However, 
previously to the formation of circulatory system, human embryonic development occurs in a 
relatively O2-poor environment (3%-4% O2)[77]. Aiming at adjusting hESC culture to physiological 
levels, we compared 4% pO2 to standard 21% pO2 conditions during hESC recovery after cryo-
preservation. After thawing, hESC were routinely cultured in E8 medium which maintains cells 
in a pluripotent state[120]. After defrosting, hESC recovery at 4% pO2 was slower, as shown by 
smaller and less abundant hESC colonies at passage 2(Figure 3.1.1. A and C). In fact, hESC at 
4% pO2 required the double of passages to attain a phenotype similar to 21% pO2 (Figure 3.1.1. 
B and D) and usable for monolayer differentiation into CMs. 
 
Figure 3.1.1. Representative brightfield images of hESC in culture at 4% and 21% pO2. A and B- hESC 
maintained 4% pO2 during 2 (A) and 8 passages (B). C and D- hESC maintained 21% pO2 during 2 (C) and 4 
passages (D). Scale bar, 1000µm. 
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3.2.  In vivo pO2 levels support CMs differentiation from hESC. 
Hypoxia is known to sustain pluripotency, thus, introducing embryonic physiological levels 
of pO2 may constitute a challenge for SC differentiation into specific lineages.  
To determine which condition was most favourable to support CM differentiation from hESC, 
an experimental setup was established (Figure 3.2.1) for pairwise comparison of the introduc-
tion of 4% pO2 at different culture stages. The standard culture condition at 21% pO2 was com-
pared with the use of 4% pO2 during all culture stages (condition 4%) and the introduction of 4% 
pO2 immediately after hESC passaging (day minus one (D-1) (condition 4%1), or on the next day 
(day zero (D0) (condition 4%2) (Figure 3.2.1). 
 
Figure 3.2.1.  A- Diagram illustrating experimental physiological pO2 setup, level, 14 day procedure. 21% 
group (control), was always kept at all stages under 21% pO2; 4% group originated from 4% SC. 4%1 and 
4%2 group have their origin on 21% SC. 4% group was always kept at all stages under 4% pO2, while 4%1 
and 4%2 group were kept at this condition during 15 and 14 days, respectively. Small grey boxes indicated 
the day of culture (D-1, D0, D3, D7 and D14). Medium group indicates to what kind of medium cells were 
cultured, SC stage cultured in E8 and differentiation stage cultured on BPEL. Timeline of differentiation 
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factors added to medium presented on grey arrow. B- Representative brightfield images of differentiated  
CMs from the groups of the diagram A CMs in culture at 4% and 21% pO2. Scale bar, 1000µm. C-  Different 
group differentiation efficiency of hESC derived CMs analysed through flow cytometry. The cells are di-
vided per differentiation group. Control-21% group, 4% group and 4%2 group. Results presented as per-
centage (%) of cells GFP (NKX 2.5)+/mRuby (-actinin)+ characteristic of CMs. Bars represent SEM.*P<0.05 
vs Control; T-Test was used for all the parameters presented. D- Flow cytometry analysis of different 
experimental groups. Gating for GFP-NKX2.5. (y axis) and mRuby- -actinin (x axis). Percentage related 
to to the two existing population GFP (NKX 2.5)+/mRuby ( -actinin)+ and GFP (NKX 2.5)-/mRuby ( -
actinin)+. At least 60 × 106 cells were analysed per group. 
 
Cardiac differentiation efficacy was initially assessed by the appearance of beating colonies 
and quantified through fluorescence analysis of the two reporters - GFP (NKX 2.5)+/mRuby (α-
actinin) – by flow cytometry. The 4%1 group failed to produce contractile CMs colonies (Figure 
3.2.1 B and C) and therefore was removed from subsequent experiments. The conditions 4% 
and 4%2 produced contractile CMs (movie 1.1-1.2. and movie 2.1-2.2, respectively) with a low 
yield. Surprisingly, the obtained CMs were only located in the edge of the well, however no 
explanation was found for this event. The control 21% pO2 group produced a full-well monolayer 
of CMs. Regarding flow cytometry, CM were identified as cells expressing NKX-2.5 and sarco-
meric α-actinin. Overall, a decrease on CM yield was observed in all conditions using the phys-
iological 4% pO2 levels, compared to the 21% control (movie 3.1-3.2). As expected, pre-condi-
tioned 4% pO2 condition presented higher yields than differentiations performed at 4% pO2 and 
21% pO2 only up to D-1. In addition, experiment-to-experiment variation was observed regarding 
the CM differentiation efficacy. 
 
3.3. Extra in vivo pO2 condition increased differentiation yield of hESC into 
CMs. 
Differentiated CMs using 4% pO2 experimental setup, gave the urge to increase the differ-
entiation yield, for that it was stablished two distinct strategies: different hESC seeding densi-
ties and extra in vivo pO2 condition (7%).  The values chosen for the different hESC seeding 
densities were based on the previous group experience, which suspected that the results ob-
tained in the first differentiation (26.3 × 106 cells/cm2) could be related to over seeding. Hence, 
CM differentiation was performed using the 4% and 4%2 conditions using six hESC seeding den-
sities ranging from 10.5 × 106 cells/cm2 to 26.3 × 106 cells/cm2 (Figure 3.3.1). The higher seeding 
densities of 21 × 106 cells/cm2 and 26.3 × 106 cells/cm2 produced better yields of CM differen-
tiation, showing that no protocol alteration was needed. In accordance to our previous results, 
the experimental group 4% resulted in more CMs than the 4%2, (movies 4-15). However, due to 
technical problems no flow cytometry was performed on this experiment to quantify the dif-
ferentiation efficiency/yield. 
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Figure 3.3.1. Representative images of 14 days CM differentiation using 4% (A) and 4%2 conditions (B) and 
different cell seeding densities. Each image, from left to right and top to bottom, represents hESC 
increasing densities. Scale bar, 1000µm. 
 
After the third month of gestation is explicit on literature another in vivo pO2 condition 
(7%)[81] and it was added to increase the differentiation efficiency. In this setup, instead of 
maintaining the the cells for 14 days at 4% pO2, they were transferred to an incubator at 7% at 
day 7 and kept until day 14 in this condition as demonstrated on the scheme (Figure 3.3.3). 
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Figure 3.3.2. A-  Diagram illustrating experimental physiological pO2 setup with extra 7% O2 level, 14-day 
procedure. 21% group (control), was always kept at all stages under 21% pO2; 7% group originated from 
4% SC. 7%2 group have their origin on 21% SC. During differentiation, cells instead of being during 14 days 
at 4% pO2 they are placed at 7% pO2 at day 7 of the experiment. Small grey boxes indicated the day of 
culture (“D-1”, “D0”, “D3”, “D7” and “D14”). Medium group indicates to what kind of medium cells were 
cultured, SC stage cultured in E8 and differentiation stage cultured on BPEL.  Timeline of differentiation 
factors added to medium presented on grey arrow. B and C- Representative images of 14 days CM 
differentiation using 7% (B) and 7%2 conditions (C) and different cell seeding densities. Each image, from 
left to right and top to bottom, represents hESC increasing densities. Scale bar, 1000µm. 
To evaluate if different seeding densities would have an impact on CM differentiation using 
this setup (conditions 7% and 7%2), different cells densities were used as in the previous exper-
iment.  
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Once again, the different seeding densities showed that no protocol alteration was needed, 
since seeding densities of 21 × 106 cells/cm2 and 26.3 × 106 cells/cm2, which were already being 
used during experiments, showed better results. It was also observed that once again the ex-
perimental group that uses 4% during hESC maintenance provided more CMs (Figures 3.3.2. and 
movies 16-27)).  
To further quantify and compare CM yields under embryonic physiological oxygen tension 
with the conventional 21% group, flow cytometry was performed.  
 
 
Figure 3.3.3. A-  Diagram illustrating complete experimental physiological pO2, 14-day procedure. 21% 
group (control), was always kept at all stages under 21% pO2; 4% group originated from 4% SC. 4%1 and 
4%2 group have their origin on 21% SC. 4% group was always kept at all stages under 4% pO2, while 4%2 
group was kept at this condition for 14 days. 7% group originated from 4% SC. 7%2 group have their origin 
on 21% SC. During differentiation, cells instead of being during 14 days at 4% pO2 they are placed at 7% 
pO2 at day 7 of the experiment. Small grey boxes indicated the day of culture (“D-1”, “D0”, “D3”, “D7” 
and “D14”). Medium group indicates to what kind of medium cells were cultured, PSC stage cultured in 
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E8 and differentiation stage cultured on BPEL. Timeline of differentiation factors added to medium pre-
sented on grey arrow.  B- Different group differentiation efficiency of hESC derived CMs analysed through 
flow cytometry. The cells are divided per differentiation group. Control-21% group, 7%group, 4% group, 
7%2 group and 4%2 group. Results presented as percentage (%) of cells GFP (NKX 2.5)+/mRuby (-actinin)+ 
characteristic of CMs. Bars represent SEM.*P<0.05 vs Control, T-Test was used for all the parameters 
presented. C-  Flow cytometry analysis of different experimental groups. Gating for GFP-NKX2.5. (y axis) 
and mRuby- -actinin (x axis). Percentage related to to the two existing population GFP (NKX 
2.5)+/mRuby ( -actinin)+ and GFP (NKX 2.5)-/mRuby ( -actinin)+. At least 60 × 106 cells were analysed 
per group. D- Represent impact of 7% pO2 condition on differentiation yield through fold increase 7%vs4% 
and 7%2 vs 4%2.  
Flow cytometry once more evidenced the variability regarding differentiation efficiency 
obtained between experiments as demonstrated by big error bars. CM differentiation under 
conventional 21% pO2 was evidently more robust when compared to the other groups (Figure 
3.3.3 B). In addition, the 7% (movie 30) and 7%2 (movie 31) conditions were not able to improve 
the differentiation outcome, when compared to the 4% (movie 28) and 4%2 groups (movie 29) . 
Of interest, the insurgence of a second population GFP (NKX 2.5)-/mRuby ( -actinin)+ that may 
be impacting the final outcome of the differentiations was evident in flow cytometry analysis 
(Figure 3.3.3C). This population, that expresses the CM marker α-actinin but shows no detect-
able levels of NKX2.5., has been previously described as a cardiac pacemaker-like popula-
tion[121].  
Since variability on CM differentiation was observed across experiments, and the analysis 
from in Figure 3.3.3 B results from 3 independent experiments, we hypothesized that this var-
iability may be masking differences across groups. Hence, to further understand the impact of 
the 7% condition we analysed the fold increase in CMs, relative to the equivalent 4% pO2 groups, 
per experiment (Figure 3.3.3. D). This analysis revealed an increment of ~1.5-fold in the 7% 
condition, when compared to the 4% group, and an increase of ~1.3 in the 7%2 group, relative 
to the 4%2. Although, the number of independent experiments is limited, especially regarding 
the 7%2 (n=1), the 7% pO2 strategy improved the CM differentiation in 5 independent experi-
ments.  
 
3.4. Differentiation of hESC into CMs using embryonic pO2 levels affects ex-
pression of metabolic- and contraction-associated genes. 
 
Since previous studies have reported that hPSC-CM resemble human fetall-CM based on gene 
expression[122] we assessed the degree of CM maturity generated under physiological O2 ten-
sion, relative to the standard 21%pO2 group. The expression of a set of genes related to metab-
olism, in particular glucose transport (PGC-1, PDK1, LDHB, HADHB, GLUT-1, GLUT-4, HK1, 
HK2) and fatty acid handling (CPT-1 and PPAR), as well as genes related to CM contraction 
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such as calcium handling genes (PLN and SERCA2) and contraction apparatus (MYH6, MYH7 and 
MYBPC3), was evaluated by q-PCR at differentiation day 14. 
 
Figure 3.4.1. Heatmap expression of genes encoding metabolic glucose transporters (GLUT-1, GLUT-4, 
HK1, HK2, HADHB, LDHB, PDK1), metabolic fatty acid mediators (PPAR, CPT-1), sarcomeric proteins 
(MYH6, MHY7, MYBPC3), calcium handling channels (PLN, SERCA2) and the mitochondrial master regulator 
PGC1α. Data was normalized to RPLP expression and is related to the 21% (14d) group. From all the group 
condition 3 n 5. 
The heatmap demonstrated that overall gene expression is different in 7%, 4% and 7%2 
groups, when compared to 21% pO2 was altered (Figure 3.4.1.). In contrast, the 4%2 group gene 
expression resembles more the 21% condition regarding the expression of the analysed genes.  
The heatmap also reveal that PGC-1, a mediator of the transition from the glycolytic me-
tabolism to OXPHOS metabolism, has increased expression on 4% and 7%, relative to the other 
culture conditions (Figure 3.4.1). For this reason, from this point onwards we proceeded only 
with condition 4% and 7%.  
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Figure 3.4.2. qPCR gene expression analysis of day 14 of CM differentiation in conventional (21%) and 
embryonic O2 tension (7% and 4%). Graph bars represent fold increase relative to the 21% group after 
normalization to the RPLP0 housekeeping gene. Data are expressed as mean ± SEM. Data was obtained 
from 3 independent experiments. 
 
Glucose transport metabolic associated genes such as LDHB, HK1, HK2, GLUT-4 presented 
an increase expression while PDK1, HADHB and GLUT-1 the expression was not altered compar-
ing to control.  
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Fatty acid metabolic genes CPT-1 and PPAR and calcium handling genes PLN and SERCA2 
were increased in 7% and 4% groups, relative to 21% (Figure 3.4.1.). Contractile machinery 
genes related to the myosin heavy chain unit, MYH7 and MYBPC3, revealed augmented expres-
sion while MYH6 kept stable (Figure 3.4.1.). To further understand whether physiological O2 
tension is resulting in CMs on a more mature stage, we analysed the ratio of genes related to 
different stages of CM development. For example, higher expression of GLUT-1, HK1 and MYH6 
are related to a more immature stage, while higher expression of GLUT-4, HK2 and MYH7 cor-
relates to a more mature CM.  
 
3.5. Differentiation of hESC into CMs using embryonic pO2 levels does not im-
pact on mitochondria spatial localization. 
 
During metabolic maturation, mitochondria increase in number, through an equilibrium of 
fusion and fission [123], increase invagination of membranes and align with CM sarcomeres by 
migrating from the perinuclear area. To understand whether CMs differentiated in physiological 
O2 tension show mitochondrial alterations compatible with CM maturation, we co-stained the 
nucleus, sarcomeric α-actinin and mitochondria. No substantial differences were found be-
tween experimental groups on mitochondria localization. Of note, binuclear cells were found 
on the 4% and 7% group, compared to the 21% control.  
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Figure 3.5.1. Representative images of sarcomeres (α-actinin, MRUBY) and mitochondria (CY5) of differ-
entiated CM using embryonic 4% (B) and 7% (C) pO2 levels, relative to 21% (A) control condition. Scale bar 
represent 27600 (A) 18440 nm (B and C). 
 
3.6. Simulation of birth O2 tension on differentiated CMs affects gene expres-
sion of genes associated with CM metabolic and contraction. 
Afterbirth, the neonate starts to breath independently and the diet is also changed, greatly 
impacting on the maturation of the heart. In line with this, we designed a new experimental 
procedure to simulate this “birth shock” in vitro. For that an O2 tension of 10% was introduced 
at day 14 of culture until day 21. Substrate-wise, to mimic in vivo physiology we used a CM 
medium supplemented with 5mM glucose (Glc) and 30mM fatty acids (FA) (linoleic acid). A 
schematic representation of all the tested conditions is summarized in Figure 3.6.1.  
 
 
Figure 3.6.1. Diagram illustrating experimental setup designed to drive CMs under physiological oxygen 
tensions and specifically, to promote the impact of "birth shock" (increase of oxygen tension, as well 
introduction to physiological glucose and fatty acids levels). The 4% group (blue colour) either with the 
BPEL medium for the 21 days and the BPEL medium until day 14 plus CM medium for the final 7 days. The 
7% group (green colour) either with the BPEL medium for the 21 days and the BPEL medium until day 14 
plus CM medium for the final 7 days. In the 10% group (orange colour) we tested the CM medium with 5mM 
Glucose and 30mM FA as the ideal and final condition. The remaining subgroups of 10% are controls of 
medium conditions.  
Gene expression analysis of the panel of genes related to metabolism and CM contraction 
studies in previous experiments further highlighted cultured conditions driving CM maturation 
(Figure 3.6.2). 
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Figure 3.6.2. Heatmap expression of genes encoding metabolic glucose transporters (GLUT-1, GLUT-4, 
HK1, HK2, HADHB, LDHB, PDK1), metabolic fatty acid mediators (PPAR, CPT-1), sarcomeric proteins 
(MYH6, MHY7, MYBPC3), calcium handling channels (PLN, SERCA2) and the mitochondrial master regulator 
PGC1α. Data was normalized to RPLP expression and is related to the 21% (14d) group. From all the group 
condition 3 n 5. 
Overall, the “birth shock” experimental setup (10% pO2 with Glc and FA) resulted on dra-
matic changes on gene expression compared to the standard 21% group (Figure 3.6.2 and 3.6.3). 
The 10% pO2 with Glc and FA experimental subgroup showed increased expression of PGC-1, of 
the glucose transport metabolic genes HK2 and GLUT-4 and the calcium handling genes PLN and 
SERCA2. Contractile machinery genes related to the myosin heavy chain unit, MYH7 and MYBPC3, 
also revealed augmented expression while MYH6 was decreased (Figure 3.6.2 and 3.6.3). The 
expression ratio of genes related to different stages of CM development also demonstrated a 
generalized fold increase in CM maturation-related genes in the 10% pO2 with Glc and FA group, 
compared to standardized 21% group.  
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Figure 3.6.3. qPCR gene expression analysis of day 21 of CM differntiation in conventional (21%) and 
embryonic O2 tension (7% and 4%). Graph bars represent fold increase relative to the 21% group afternor-
malization to the RPLP0 housekeeping gene. Data are expressed as mean ± SEM .data was obtained from 
1 independent experiments. 
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3.7. Simulation of birth O2 tension on differentiated CMs increases the number 
of mitochondria. 
 
Mitotracker detection by flow cytometry allowed the asessement of mitochondria develop-
ment i.e. more signal intensity correlates with more mitochondria in the cell.  
 
 
Figure 3.7.1. Mitochondria quantification per experimental subgroup. Histograms show M-labeled cells 
(gated based on GFP expression) in the 21% and 10% CM + Glc (5mM) + FA (30mM) groups. At least 10,000 
cells were analysed per group. C) Graph bar showing the median Mitotacker intensity per pO2 subgroup. 
Negative control - CMs from the 21% group without Mitotracker; Positive control- CMs from the 21% group 
stained with Mitotracker.  
Flow cytometry analysis of the Mytotracker revealed existence of a two CMs population with 
two discrete Mitotracker intensity signals (Figure 3.7.1.). The impact of “birth shock” experi-
ment in mitochondria development was evaluated through the calculation of median intensity 
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value per experimental subgroup (Figure 3.7.2.). At 4% and 7% group, the cells culture on CM 
medium presented higher median intensity, while in the 10% group no differences were de-
tected between the two media. All subgroups showed substantial difference to control. 
 
3.8.  hESC derived CMs seeding and maintenance on a I/R disease model chip. 
Microfluidic chips contain small volumes, they have high internal resistances, applying very 
small variations in temperature and medium solute concentrations that affect the inherent cell 
behaviour. Aiming at the development of a IR chip with CM for robust in vitro studies, we 
optimized the seeding of CMs on a chip. Microscopy inspection of the cells through time re-
vealed discrete phenotypic changes. Initially, CMs attached and formed colonies that started 
beating around day 2 (figure 3.8.1.B, movie 32-33). Then CMs formed bigger beating colonies. 
However, from day 5 onwards(figure 3.8.1.C, movie 34), colonies started to shrink and CM 
started to die (Figure 3.8.1.). The intended objective was to keep a confluent monolayer of CM 
on I/R chip for further studies, what revealed the need of using high seeding densities between 
approximately 3 x 106 cells/cm2 and 8 x 106 cells/cm2 and medium refreshment every 2 to 3 
days. CMs could produce a compact monolayer with several colonies beating observable on 
bright field and fluorescence -actinin linked videos of figure 3.8.1.  Equal seeding density was 
achieved in every channel. 
 
 
Figure 3.8.1. Imaging of organ-on-a-chip I/R model CMs maintenance using  bright field and fluorescence 
m-Ruby -actinin microscopy. A) Day zero bright field microscopy B) Third day bright field and 
fluorescence microscopy C) Fifth day bright field and fluorescence microscopy. Scale bar, 300µm. 
 
 
 
 
 
3.9. Mechanical stimulation chip, hESC derived CMs seeding and maintenance 
optimization. 
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Cells react to the mechanical stimuli input from the surrounding cells and tissues and CMs, 
in particular, are cells under constant mechanical stress. To understand the impact mechanical 
stimuli on hESC derived CMs, the latter were cultured on an organ chip[124] capable of produc-
ing cell straining through a malleable membrane, on the pillars area. Following CM seeding 
Microscopy examination of the CMs through time revealed a heterogeneous cell density along 
the entire chip (figure 3.9.1. A, movie 35), at day one there is evident cell decreasing from the 
channel closer to the inlet where the CMs seeding was done. Also CMs that could form contrac-
tile structures were not aligned on  the pillars, area where the stretching of the membranes 
occurs applying the forces to the cells (Figure 3.9.1.C, movie 37). 
 
 
Figure 3.9.1. Imaging of organ-on-a-chip mechanical model CMs maintenance using  bright field and 
fluorescence m-Ruby -actinin microscopy. A) Day one from left to right, channel 1 to channel 5, 
bright field microscopy B) Day one (left image) day two (right image)fluorescence microscopy (movie 
36) C) Sixth day, pillar with CMs (left image) channels with CMs (right image) bright field microscopy. 
Scale bar, 300µm (A and B), 100µm (C).  
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4. Discussion 
 
The initial idea of this project was to recreate an ischemia reperfusion model on an organ-
on -a-chip device. However, hESC derived CMs showed an immature phenotype which impaired 
the development of a model that could reproduce with fidelity the disease scenario. For this 
reason, this master thesis project was mainly devoted to improve the maturation of hESC-de-
rived CMs that could then be used for appropriate ischemia reperfusion modelling. Accordingly, 
this thesis project aimed to deliver proof of principle results showing that the use of physiolog-
ical O2 tension impacts on the differentiation of CM from hESC, by driving CMs into a more 
mature stage. In line with this, we envisaged to recreate in vitro the final stage of CM matura-
tion mimicking the impact of birth on CMs. For that, we selected two main alterations observed 
around birth i.e. the increase on O2 levels, as a result of the beginning of independent air 
breathing, and the change on the diet, characterized by an increase on fatty acids and decrease 
on sugars. To ultimately recreate the “birth shock” in vitro by rising O2 levels, CM differentia-
tion was firstly established in hypoxic conditions. So the first challenge of this work was to 
produce hESC colonies at 4% pO2, an O2 tension that mimicked the embryonic cardiac environ-
ment. The second challenge, was to differentiate hESC into CMs also using the 4% pO2 condition. 
The latter was accomplished but with less differentiation efficiency compared to controls. In-
troducing 7% groups increased differentiation yield.  
At this point, flow cytometry analysis showed existence of two cardiac cell populations, 
ventricular CMs (GFP (NKX 2.5)+/mRuby (-actinin)+ ), and a GFP (NKX 2.5)-/mRuby (-ac-
tinin)+  population,  most likely a pacemaker-like cell population . This goes in line with the 
development of the heart, in which pacemakers and myocardial working-CM derive from a com-
mon developmental precursor.[121]. Differentiation of cells from a SC population is a biological 
process technically demanding, in which differentiation efficacy can diverge greatly across ex-
periments. Using our protocol, we obtained a heterogeneous population on control group with 
CMs but also non-expression cells for NKX2.5 and α-actinin, most likely fibroblasts and other 
mesodermal lineage cells. These populations, could have impacted the gene expression of our 
samples, since expression analysis was performed in the entire population at day 14. Hence, 
our gene expression results provided an indicative and comparative result rather than a direct 
assessment of the maturation status. Gene study of the FACS-sorted CMs population, using the 
fluorescent reporters, would have been ideal, however was not possible in time-frame of this 
project. Relative to standard 21% pO2 culture conditions, alteration on gene expression were 
observed using embryonic O2 tension towards the differentiation of more mature CMs. Indeed, 
upregulation o PPGC-1a, GLUT-4, MYH7, SERCA2 and PLN and downregulation of MYH6, which 
we observe using physiologic O2, has been associated by Ronaldson-Bouchard [125] with CM 
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maturity, while using mechanical and electrical stimuli to drive CM maturation. We observed 
upregulation on PGC-1, driving CMs into a OXPHOS metabolism, fatty acid nuclear signal 
transducer (PPAR-) and mitochondrial transporter (CPT-1b) in 4% and 7% group, compared to 
21% pO2. Contractile system also revealed a tendency for improved maturation with increase 
expression of calcium handling genes, SERCA2 and PLN, giving more stable contraction to CMs. 
The mechanical machinery from the contractile system also revealed a displacement towards 
an adult-like CM phenotype, revealing a fold increase on the MYH7/MYH6 ratio, particularly on 
7% group, and as well an increment on cardiac specific myosin heavy chain MYBPC3, on both 
groups. 
Herein, the ultimate attempt to drive CMs maturation was attained by mimicking birth al-
teration, namely through an increase in O2 tension (10% pO2) and supplementation with low 
glucose and fatty acids. Gene expression on birth shock experiment is only related to one ex-
periment, however, a clear indication of improved CM maturation was obtained and, therefore, 
a strong investment should be made to increase experimental replicates. Indeed our results are 
in line with others, which demonstrated that glucose reduction resulted in CM with more α-
actinin staining, more mitochondria and higher PLN and MYH7 expression. In the same work, 
high levels of glucose suppressed the expression of PGC-1. These findings go in line to what 
we observe in Figure 3.7.1. where 5mM Glc produce higher median intensity than same condi-
tion with 15mM of Glc, in Figure 3.6.3. explicit in the case of PGC1-. Also accordance to our 
results, Marc van Bilsen[127], using physiological levels of FA,  reported an increment on PPAR-
a expression and reduction on HK2 and GLUT-4 ratios. Adding to this John M. Brandt [128] 
correlated the increase expression of PPARa with the shown increase expression of CPT-1b when 
cells are exposed to FA.  
To unequivocally demonstrate that physiological oxygen tension improves CM maturation, 
it would be important to increase the number of independent experiments, but also other depth 
analysis are required, such as transmission electron microscopy and studies on action potential. 
In addition, time in culture is a fundamental step to achieve greater CMs maturity[129] and 
many of our analysis were performed at day 14 of differentiation, a few days after the cells 
start to beat. However, through the use of physiological oxygen tension we were able to ob-
served an important detail of CM maturation, de binucleation of the cell[129], it was only ob-
served on 4% and 7% population (Figure 3.5.1) which advocates CM maturity in our experimental 
setting. 
Mitochondria through development increases in number in response to higher energetic de-
mands from CMs, and also intensifies membrane invagination[130]. Since mitochondrial devel-
opment is an important feature during metabolic maturation of CMs[130], we analysed mito-
chondria using Mitotracker, which binds to thiols groups of the mitochondrial membranes. Mi-
tochondria/mitochondrial invagination on 4%, 7% and 10 % groups was higher, relative to the 
conventional 21% pO2 condition. Also, CM medium is known from group experience (unpublished 
data) to drive CMs into a more mature state, which was noticeable by comparing 4% and 7% CM 
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(15mM Glc) subgroups with 4% and 7% BPEL (15mM Glc) with the increased Mitotracker mean 
intensity.  
Regarding the I/R disease model chip, the latter showed suitable properties to maintain 
CMs even with low medium refreshment comparing to the final using method where will have 
a continuous flux created by a pump system, providing fresh medium while in normal/reperfu-
sion situation or only providing the flux to the external channel (s) in order to promote the 
ischemia gradient. In what concerns the mechanical stimuli chip, it needed optimization be-
cause of the big surface area of the chip (56cm2), requiring 12 x 106 cells for seeding, which 
enabled further studies in the timeframe of this work. Also , the interconnected channels were 
not able to provide “multiplexing” of the impact of mechanical stimuli and area of stimuli input 
was too small (ratio area stimuli/total area). These limitation were reported to the collabora-
tion group which designed the chip, accompanied by some proposals on design alterations. 
Overall, this work contributed to demonstrate that O2 tension during in vitro cardiac dif-
ferentiation impacts on CM maturation and that mimicking physiological O2 levels and diet may 
significantly improve the generation of mature CMs in vitro, thus, contributing to the genera-
tion of robust disease models for high-throughput drug testing. 
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5. Conclusion 
 
Natural engineering philosophy has proven that is worth the effort to mimic what we ob-
serve in the human body, the conjugation of conditions is limitless but firstly, steady individual 
results should be obtained to narrow our aim to specific conditions and objectvies. Results 
showed that is possible to obtain CMs using pO2 values consider wrongly as hypoxic. To obtain 
hESC-derived CMs is by itself a complex and variable process, using the physiological O2 condi-
tions increases this variability, leading to urge for protocol optimization. In vivo pO2 differen-
tiation of hESC-derived CMs, had an impact on gene expression of most genes choosed, in line 
to what is observed in maturational markers of adult CMs. Simulation of the birth impact also 
added extra maturational landscape on gene expression and mitochondrial development. 
Organ-on-a-chip is revealing to be a breakthrough technology, however a lot of time is 
needed to develop a single model, where all the conditions to mimic the disease/tissue model 
with easy manoeuvring and high throughput, demand an exhaustive and detailed work, urging 
the creation of more interdisciplinary groups to tackle in once all the problems that could 
appear, biological, mechanical, electronical or chemistry related issues.  
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